Health Care Related Organization – Page 72

Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Oncology Pipeline, Pfizer, Phase 3 trials

Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials

Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results

1 year ago talkbio0Tagged boehringer ingelheim, Idiopathic Pulmonary Fibrosis, NDA, nerandomilast, Phase 3, Pulmonary Fibrosis

Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design

1 year ago talkbio0Tagged Approved, AstraZeneca, Benefit, Continuance of life, Imfinzi, MIBC, muscle-invasive bladder cancer, trial design, United States Food and Drug Administration

AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit

Bristol Myers Terminates Partnership with Immatics on Bispecific Cancer Drug After $150M Investment

1 year ago talkbio0Tagged bispecific cancer, Immatics, Investments, Myers, partnership termination, squibb

Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment

AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies

1 year ago talkbio0Tagged AbbVie, Antibody-Drug, Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Daiichi, Immunostimulating conjugate (antigen), Neoplasms, Pfizer, Sankyo

AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology

Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer

1 year ago talkbio0Tagged Combined Modality Therapy, first-line, LAG-3/PD-1, Malignant neoplasm of lung, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy

ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

1 year ago talkbio0Tagged Advanced phase, AstraZeneca, durvalumab, ESMO24, Imfinzi, Imjudo, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma, Overall Survival, tremelimumab

AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

1 year ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial